Neeltje A Kootstra

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2121723/publications.pdf

Version: 2024-02-01

183	8,353	81434	66518
papers	citations	41 h-index	82 g-index

203	203	203	16719
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers. Clinical Infectious Diseases, 2023, 76, e533-e536.	2.9	7
2	Evolution of Coronavirus Disease 2019 (COVID-19) Symptoms During the First 12 Months After Illness Onset. Clinical Infectious Diseases, 2022, 75, e482-e490.	2.9	51
3	Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years. Journal of Infectious Diseases, 2022, 225, 1581-1591.	1.9	3
4	A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern. Cell Reports Medicine, 2022, 3, 100486.	3.3	16
5	SARSâ€CoVâ€2 infection activates dendritic cells via cytosolic receptors rather than extracellular TLRs. European Journal of Immunology, 2022, 52, 646-655.	1.6	9
6	A Prospective Five-Year Follow-up After peg-Interferon Plus Nucleotide Analogue Treatment or no Treatment in HBeAg Negative Chronic Hepatitis B Patients. Journal of Clinical and Experimental Hepatology, 2022, 12, 735-744.	0.4	5
7	Quantified integrated hepatitis B virus is related to viral activity in patients with chronic hepatitis B. Hepatology, 2022, 76, 196-206.	3.6	14
8	Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients. Blood Advances, 2022, 6, 1537-1546.	2.5	45
9	Similar Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Similar Nucleocapsid Antibody Levels in People With Well-Controlled Human Immunodeficiency Virus (HIV) and a Comparable Cohort of People Without HIV. Journal of Infectious Diseases, 2022, 225, 1937-1947.	1.9	9
10	Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study. Journal of NeuroVirology, 2022, 28, 54-63.	1.0	9
11	Reply. Hepatology, 2022, 76, E24-E24.	3.6	1
12	Identification of a Novel HBV Encoded miRNA Using Next Generation Sequencing. Viruses, 2022, 14, 1223.	1.5	5
13	Identification of 2-(4-N,N-Dimethylaminophenyl)-5-methyl-1-phenethyl-1H-benzimidazole targeting HIV-1 CA capsid protein and inhibiting HIV-1 replication in cellulo. BMC Pharmacology & Toxicology, 2022, 23, .	1.0	0
14	Telomere Length, Traditional Risk Factors, Factors Related to Human Immunodeficiency Virus (HIV) and Coronary Artery Disease Events in Swiss Persons Living With HIV. Clinical Infectious Diseases, 2021, 73, e2070-e2076.	2.9	7
15	Human Immunodeficiency Virus (HIV)-Negative Men Who Have Sex With Men Have Higher CD8+ T-Cell Counts and Lower CD4+/CD8+ T-Cell Ratios Compared With HIV-Negative Heterosexual Men. Journal of Infectious Diseases, 2021, 224, 1187-1197.	1.9	8
16	Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. Science, 2021, 371, .	6.0	244
17	The Complement Pathway Is Activated in People With Human Immunodeficiency Virus and Is Associated With Non-AIDS Comorbidities. Journal of Infectious Diseases, 2021, 224, 1405-1409.	1.9	7
18	Nef Obtained from Individuals with HIV-1 Vary in Their Ability to Antagonize SERINC3- and SERINC5-Mediated HIV-1 Restriction. Viruses, 2021, 13, 423.	1.5	7

#	Article	IF	Citations
19	Sexual Behavior and Its Determinants During COVID-19 Restrictions Among Men Who Have Sex With Men in Amsterdam. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 288-296.	0.9	46
20	Impact of Delaying Antiretroviral Treatment During Primary Human Immunodeficiency Virus Infection on Telomere Length. Journal of Infectious Diseases, 2021, , .	1.9	2
21	Cell-Associated HIV-1 Unspliced-to-Multiply-Spliced RNA Ratio at 12 Weeks of ART Predicts Immune Reconstitution on Therapy. MBio, 2021, 12, .	1.8	12
22	Changes in lung function among treated HIV-positive and HIV-negative individuals: analysis of the prospective AGEhIV cohort study. The Lancet Healthy Longevity, 2021, 2, e202-e211.	2.0	20
23	Generally rare but occasionally severe weight gain after switching to an integrase inhibitor in virally suppressed AGEhIV cohort participants. PLoS ONE, 2021, 16, e0251205.	1.1	8
24	Coronary Artery Diseaseâ€“Associated and Longevity-Associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living With Human Immunodeficiency Virus: The Swiss HIV Cohort Study. Clinical Infectious Diseases, 2021, 73, 1597-1604.	2.9	5
25	Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapy. ELife, 2021, 10, .	2.8	10
26	Hepatitis B core related antigen in relation to intrahepatic and circulating viral markers, before and after combination therapy. Annals of Hepatology, 2021, 26, 100540.	0.6	7
27	Infection and transmission of SARSâ€CoVâ€2 depend on heparan sulfate proteoglycans. EMBO Journal, 2021, 40, e106765.	3.5	50
28	Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study. Journal of Viral Hepatitis, 2021, 28, 1690-1698.	1.0	21
29	Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol. Frontiers in Immunology, 2021, 12, 753319.	2.2	13
30	CD9 and ITGA3 are regulated during HIV-1 infection in macrophages to support viral replication. Virology, 2021, 562, 9-18.	1.1	3
31	Plasma Inflammatory Biomarkers Predict CD4+ T-cell Recovery and Viral Rebound in HIV-1 Infected Africans on Suppressive Antiretroviral Therapy. Journal of Infectious Diseases, 2021, 224, 673-678.	1.9	4
32	High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis. Journal of Hepatology, 2020, 72, 855-864.	1.8	48
33	Genetic variations in the host dependency factors ALCAM and TPST2 impact HIV-1 disease progression. Aids, 2020, 34, 1303-1312.	1.0	1
34	MAVS Genetic Variation Is Associated with Decreased HIV-1 Replication In Vitro and Reduced CD4+ T Cell Infection in HIV-1-Infected Individuals. Viruses, 2020, 12, 764.	1.5	3
35	Human Immunodeficiency Virus-Negative Men Who Have Sex With Men Have an Altered T-Cell Phenotype and Bioenergy Metabolism. Open Forum Infectious Diseases, 2020, 7, ofaa284.	0.4	2
36	Monocyte and T Cell Immune Phenotypic Profiles Associated With Age Advancement Differ Between People With HIV, Lifestyle-Comparable Controls and Blood Donors. Frontiers in Immunology, 2020, 11, 581616.	2.2	4

#	Article	IF	Citations
37	Immune activation correlates with and predicts CXCR4 co-receptor tropism switch in HIV-1 infection. Scientific Reports, 2020, 10, 15866.	1.6	19
38	HIV-associated gut dysbiosis is independent of sexual practice and correlates with noncommunicable diseases. Nature Communications, 2020, 11, 2448.	5.8	97
39	Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science, 2020, 369, 643-650.	6.0	1,104
40	CD32+CD4+ T Cells Are Highly Enriched for HIV DNA and Can Support Transcriptional Latency. Cell Reports, 2020, 30, 2284-2296.e3.	2.9	35
41	Novel Orthobunyavirus Identified in the Cerebrospinal Fluid of a Ugandan Child With Severe Encephalopathy. Clinical Infectious Diseases, 2019, 68, 139-142.	2.9	35
42	THU-210-HBcrAg levels at baseline are not predictive for HBsAg and HBeAg loss in patients treated with adefovir and PEG-interferon. Journal of Hepatology, 2019, 70, e256.	1.8	0
43	Do people living with HIV experience greater age advancement than their HIV-negative counterparts?. Aids, 2019, 33, 259-268.	1.0	93
44	Systemic and intrathecal immune activation in association with cerebral and cognitive outcomes in paediatric HIV. Scientific Reports, 2019, 9, 8004.	1.6	17
45	Plasma Biomarkers of Human Immunodeficiency Virusâ€"Related Systemic Inflammation and Immune Activation in Sub-Saharan Africa Before and During Suppressive Antiretroviral Therapy. Journal of Infectious Diseases, 2019, 220, 1029-1033.	1.9	36
46	Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance. Journal of Hepatology, 2019, 71, 14-24.	1.8	27
47	The Role of Macrophages in HIV-1 Persistence and Pathogenesis. Frontiers in Microbiology, 2019, 10, 2828.	1.5	123
48	Sexually transmitted founder HIV-1 viruses are relatively resistant to Langerhans cell-mediated restriction. PLoS ONE, 2019, 14, e0226651.	1.1	14
49	Structural Brain Abnormalities in Successfully Treated HIV Infection: Associations With Disease and Cerebrospinal Fluid Biomarkers. Journal of Infectious Diseases, 2018, 217, 69-81.	1.9	40
50	CNS penetration of ART in HIV-infected children. Journal of Antimicrobial Chemotherapy, 2018, 73, 484-489.	1.3	21
51	Multiplex flow cytometry-based assay to study the breadth of antibody responses against E1E2 glycoproteins of hepatitis C virus. Journal of Immunological Methods, 2018, 454, 15-26.	0.6	3
52	Patterns of Co-occurring Comorbidities in People Living With HIV. Open Forum Infectious Diseases, 2018, 5, ofy272.	0.4	35
53	Systemic <scp>DPP</scp>4 activity is reduced during primary <scp>HIV</scp>â€1 infection and is associated with intestinal <scp>RORC</scp>⁺<scp>CD</scp>4⁺ cell levels: a surrogate marker candidate of <scp>HIV</scp>â€induced intestinal damage. Journal of the International AIDS Society, 2018, 21, e25144.	1.2	16
54	Deep sequencing identifies hepatitis B virus core protein signatures in chronic hepatitis B patients. Antiviral Research, 2018, 158, 213-225.	1.9	0

#	Article	IF	Citations
55	The â€˜COmorBidity in Relation to AIDSâ€™ (COBRA) cohort: Design, methods and participant characteristics. PLoS ONE, 2018, 13, e0191791.	1.1	12
56	Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial. Lancet, The, 2017, 389, 709-717.	6.3	204
57	<scp>NK</scp> cells in selfâ€limited <scp>HCV</scp> infection exhibit a more extensively differentiated, but not memoryâ€like, repertoire. Journal of Viral Hepatitis, 2017, 24, 917-926.	1.0	12
58	Plasma MicroRNA Levels Are Associated With Hepatitis B e Antigen Status and Treatment Response in Chronic Hepatitis B Patients. Journal of Infectious Diseases, 2017, 215, 1421-1429.	1.9	52
59	Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of antiâ€MicroRNAâ€122, RGâ€101. Hepatology, 2017, 66, 57-68.	3.6	39
60	HIV-1 blocks the signaling adaptor MAVS to evade antiviral host defense after sensing of abortive HIV-1 RNA by the host helicase DDX3. Nature Immunology, 2017, 18, 225-235.	7.0	109
61	Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing. Antiviral Research, 2017, 146, 139-145.	1.9	14
62	Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. Journal of Experimental Medicine, 2017, 214, 2573-2590.	4.2	151
63	Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report. Lancet HIV,the, 2017, 4, e522-e528.	2.1	69
64	Contributors to immune senescence during treated HIV-1 infection. Experimental Gerontology, 2017, 94, 125-126.	1.2	0
65	Viral minority variants in the core promoter and precore region identified by deep sequencing are associated with response to peginterferon and adefovir in HBeAg negative chronic hepatitis B patients. Antiviral Research, 2017, 145, 87-95.	1.9	12
66	Human intrahepatic CD69â€‰+â€‰CD8+ T cells have a tissue resident memory T cell phenotype with reduced cytolytic capacity. Scientific Reports, 2017, 7, 6172.	1.6	94
67	Dynamics of the Immune Response in Acute Hepatitis B Infection. Open Forum Infectious Diseases, 2017, 4, ofx231.	0.4	16
68	Terminal differentiation of T cells is strongly associated with CMV infection and increased in HIV-positive individuals on ART and lifestyle matched controls. PLoS ONE, 2017, 12, e0183357.	1.1	34
69	HIV testing week 2015: lowering barriers for HIV testing among high-risk groups in Amsterdam. BMC Infectious Diseases, 2017, 17, 529.	1.3	10
70	High Cellular Monocyte Activation in People Living With Human Immunodeficiency Virus on Combination Antiretroviral Therapy and Lifestyle-Matched Controls Is Associated With Greater Inflammation in Cerebrospinal Fluid. Open Forum Infectious Diseases, 2017, 4, ofx108.	0.4	17
71	Inflammatory and Neuronal Biomarkers Associated With Retinal Thinning in Pediatric HIV. , 2017, 58, 5985.		4
72	Hepatitis B Virus Protein X Induces Degradation of Talin-1. Viruses, 2016, 8, 281.	1.5	28

#	Article	IF	Citations
73	Elevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease Onset. PLoS Pathogens, 2016, 12, e1005774.	2.1	50
74	Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy. Aids, 2016, 30, 1027-1038.	1.0	58
75	Liver fibrosis in HIV-infected individuals on long-term antiretroviral therapy. Aids, 2016, 30, 1771-1780.	1.0	31
76	Neurometabolite Alterations Associated With Cognitive Performance in Perinatally HIV-Infected Children. Medicine (United States), 2016, 95, e3093.	0.4	22
77	Difference in Aortic Stiffness Between Treated Middle-Aged HIV Type 1â€“Infected and Uninfected Individuals Largely Explained by Traditional Cardiovascular Risk Factors, With an Additional Contribution of Prior Advanced Immunodeficiency. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 55-62.	0.9	17
78	Identification of FDAâ€approved drugs that target hepatitis B virus transcription. Journal of Viral Hepatitis, 2016, 23, 191-201.	1.0	16
79	<scp>HLA</scp>â€C and <scp>KIR</scp> combined genotype as new response marker for <scp>HB</scp>eAgâ€positive chronic hepatitis B patients treated with interferonâ€based combination therapy. Journal of Viral Hepatitis, 2016, 23, 652-659.	1.0	9
80	The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype. AIDS Research and Human Retroviruses, 2016, 32, 1135-1142.	0.5	11
81	Minor Contribution of Chimeric Host-HIV Readthrough Transcripts to the Level of HIV Cell-Associated gag RNA. Journal of Virology, 2016, 90, 1148-1151.	1.5	25
82	Receptor usage dictates HIV-1 restriction by human TRIM5Î± in dendritic cell subsets. Nature, 2016, 540, 448-452.	13.7	143
83	T-Cell Activation Independently Associates With Immune Senescence in HIV-Infected Recipients of Long-term Antiretroviral Treatment. Journal of Infectious Diseases, 2016, 214, 216-225.	1.9	97
84	Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir. Antiviral Research, 2016, 131, 148-155.	1.9	15
85	Higher Prevalence of Hypertension in HIV-1-Infected Patients on Combination Antiretroviral Therapy Is Associated With Changes in Body Composition and Prior Stavudine Exposure. Clinical Infectious Diseases, 2016, 63, 205-213.	2.9	70
86	Cigarette Smoking and Inflammation, Monocyte Activation, and Coagulation in HIV-Infected Individuals Receiving Antiretroviral Therapy, Compared With Uninfected Individuals. Journal of Infectious Diseases, 2016, 214, 1817-1821.	1.9	22
87	Miravirsen dosing in chronic hepatitis C patients results in decreased micro<scp>RNA</scp>â€122 levels without affecting other micro<scp>RNA</scp>s in plasma. Alimentary Pharmacology and Therapeutics, 2016, 43, 102-113.	1.9	128
88	HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds. Retrovirology, 2016, 13, 48.	0.9	20
89	Restoration of T cell function in chronic hepatitis B patients upon treatment with interferon based combination therapy. Journal of Hepatology, 2016, 64, 539-546.	1.8	37
90	Mutations in CypA Binding Region of HIV-1 Capsid Affect Capsid Stability and Viral Replication in Primary Macrophages. AIDS Research and Human Retroviruses, 2016, 32, 390-398.	0.5	11

#	Article	IF	Citations
91	Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues. Journal of Infectious Diseases, 2016, 213, 224-232.	1.9	125
92	Identification of the HIV-1 Vif and Human APOBEC3G Protein Interface. Cell Reports, 2015, 13, 1789-1799.	2.9	57
93	An intrahepatic transcriptional signature of enhanced immune activity predicts response to peginterferon in chronic hepatitis B. Liver International, 2015, 35, 1824-1832.	1.9	17
94	Twelve-Month Antiretroviral Therapy Suppresses Plasma and Genital Viral Loads but Fails to Alter Genital Levels of Cytokines, in a Cohort of HIV-Infected Rwandan Women. PLoS ONE, 2015, 10, e0127201.	1.1	8
95	O114 : Serum HBV-RNA levels decline significantly in chronic hepatitis B patients dosed with the nucleic-acid polymer REP2139-CA. Journal of Hepatology, 2015, 62, S250.	1.8	13
96	P0659 : Cytokine responses in chronic hepatitis B patients dosed with the nucleic-acid polymer REP2139-Ca. Journal of Hepatology, 2015, 62, S567.	1.8	0
97	Inhibition of histone deacetylases stimulates HBV replication independent of protein X. Future Virology, 2015, 10, 351-356.	0.9	0
98	Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir. Journal of Infectious Diseases, 2015, 212, 1042-1051.	1.9	46
99	Infection History Determines the Differentiation State of Human CD8 ⁺ T Cells. Journal of Virology, 2015, 89, 5110-5123.	1.5	51
100	SAMHD1 Degradation Enhances Active Suppression of Dendritic Cell Maturation by HIV-1. Journal of Immunology, 2015, 194, 4431-4437.	0.4	26
101	A Lower Viral Set Point but Little Immunological Impact After Early Treatment During Primary HIV Infection. Viral Immunology, 2015, 28, 134-144.	0.6	2
102	G3BP1 restricts HIV-1 replication in macrophages and T-cells by sequestering viral RNA. Virology, 2015, 486, 94-104.	1.1	22
103	Adaptation of HIV-1 to rhTrim5Î±-mediated restriction in vitro. Virology, 2015, 486, 239-247.	1.1	6
104	Viral evolution in HLA-B27-restricted CTL epitopes in human immunodeficiency virus type 1-infected individuals. Journal of General Virology, 2015, 96, 2372-2380.	1.3	9
105	ADAR1 Facilitates HIV-1 Replication in Primary CD4+ T Cells. PLoS ONE, 2015, 10, e0143613.	1.1	16
106	DYRK1A Controls HIV-1 Replication at a Transcriptional Level in an NFAT Dependent Manner. PLoS ONE, 2015, 10, e0144229.	1.1	24
107	Polymorphism inIFI16affects CD4+T-cell counts in HIV-1 infection. International Journal of Immunogenetics, 2014, 41, 518-520.	0.8	15
108	Cross-sectional Comparison of the Prevalence of Age-Associated Comorbidities and Their Risk Factors Between HIV-Infected and Uninfected Individuals: The AGEhIV Cohort Study. Clinical Infectious Diseases, 2014, 59, 1787-1797.	2.9	617

#	Article	IF	Citations
109	HIV-1 Isolation from Infected Peripheral Blood Mononuclear Cells. Methods in Molecular Biology, 2014, 1087, 187-196.	0.4	3
110	Genetic variation in Trex1 affects HIV-1 disease progression. Aids, 2014, 28, 2517-2521.	1.0	10
111	Differential Characteristics of Cytotoxic T Lymphocytes Restricted by the Protective HLA Alleles B*27 and B*57 in HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 236-245.	0.9	4
112	P182 VIRAL PARTICLES CONTAINING HBVRNA ARE PRESENT IN PLASMA BEFORE AND DURING NUCLEOS(T)IDE ANALOGUE TREATMENT OF CHRONIC HEPATITIS B PATIENTS. Journal of Hepatology, 2014, 60, S127.	1.8	0
113	Next-generation sequencing of microRNAs in primary human polarized macrophages. Genomics Data, 2014, 2, 181-183.	1.3	13
114	Next-generation sequencing of microRNAs uncovers expression signatures in polarized macrophages. Physiological Genomics, 2014, 46, 91-103.	1.0	89
115	P685 BASELINE LIVER BIOPSY CHARACTERISTICS ASSOCIATED WITH RESPONSE IN CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON-ALFA AND ADEFOVIR. Journal of Hepatology, 2014, 60, S297.	1.8	0
116	P684 PLASMA HBV RNA AS BASELINE PREDICTOR OF RESPONSE IN CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON AND ADEFOVIR. Journal of Hepatology, 2014, 60, S297.	1.8	0
117	P181 GENE SET ENRICHMENT ANALYSIS IN BASELINE LIVER BIOPSIES OF CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON-ALFA AND ADEFOVIR. Journal of Hepatology, 2014, 60, S126.	1.8	0
118	HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels. Journal of Hepatology, 2014, 61, 730-737.	1.8	22
119	MicroRNAs: role and therapeutic targets in viral hepatitis. Antiviral Therapy, 2014, 19, 533-541.	0.6	10
120	Low level of HIV-1 evolution after transmission from mother to child. Scientific Reports, 2014, 4, 5079.	1.6	6
121	Fetal exposure to HIV-1 alters chemokine receptor expression by CD4+T cells and increases susceptibility to HIV-1. Scientific Reports, 2014, 4, 6690.	1.6	45
122	Phosphodiesterase 8a Supports HIV-1 Replication in Macrophages at the Level of Reverse Transcription. PLoS ONE, 2014, 9, e109673.	1.1	4
123	Expanded memory CD4+ CCR5+ T cells in the fetal and the infant gut; a mucosal route for mother-to-child-transmission of HIV-1. Tijdschrift Voor Kindergeneeskunde, 2013, 81, 29-29.	0.0	0
124	Identification of a new genotype of Torque Teno Mini virus. Virology Journal, 2013, 10, 323.	1.4	17
125	Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences. Blood, 2013, 121, e57-e69.	0.6	426
126	Gag sequence variation in a human immunodeficiency virus type 1 transmission cluster influences viral replication fitness. Journal of General Virology, 2013, 94, 354-359.	1.3	2

#	Article	IF	Citations
127	Chimeric HIV-1 Envelope Glycoproteins with Potent Intrinsic Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Activity*. PLoS ONE, 2013, 8, e60126.	1.1	7
128	The Presence of CXCR4-Using HIV-1 Prior to Start of Antiretroviral Therapy Is an Independent Predictor of Delayed Viral Suppression. PLoS ONE, 2013, 8, e76255.	1.1	3
129	HIV-1 Replication Fitness of HLA-B*57/58:01 CTL Escape Variants Is Restored by the Accumulation of Compensatory Mutations in Gag. PLoS ONE, 2013, 8, e81235.	1.1	13
130	HIV-1 transmission and viral adaptation to the host. Future Virology, 2012, 7, 63-71.	0.9	6
131	HIV-1 envelope diversity 1 year after seroconversion predicts subsequent disease progression. Aids, 2012, 26, 1517-1522.	1.0	7
132	Regulation of CXCR4 conformation by the small GTPase Rac1: implications for HIV infection. Blood, 2012, 119, 2024-2032.	0.6	23
133	Memory CD4+CCR5+ T cells are abundantly present in the gut of newborn infants to facilitate mother-to-child transmission of HIV-1. Blood, 2012, 120, 4383-4390.	0.6	73
134	Differential expression of HIV-1 interfering factors in monocyte-derived macrophages stimulated with polarizing cytokines or interferons. Scientific Reports, 2012, 2, 763.	1.6	85
135	HIV-1 Disease Progression Is Associated with Bile-Salt Stimulated Lipase (BSSL) Gene Polymorphism. PLoS ONE, 2012, 7, e32534.	1.1	14
136	The Hepatitis B Virus X Protein Inhibits Thymine DNA Glycosylase Initiated Base Excision Repair. PLoS ONE, 2012, 7, e48940.	1.1	20
137	Single Nucleotide Polymorphism in Gene Encoding Transcription Factor Prep1 Is Associated with HIV-1-Associated Dementia. PLoS ONE, 2012, 7, e30990.	1.1	13
138	Macrophages and HIV-1. Current Opinion in HIV and AIDS, 2011, 6, 385-390.	1.5	30
139	Loss of HIV-1-derived cytotoxic T lymphocyte epitopes restricted by protective HLA-B alleles during the HIV-1 epidemic. Aids, 2011, 25, 1691-1700.	1.0	25
140	Comparison of in vivo and in vitro evolution of CCR5 to CXCR4 coreceptor use of primary human immunodeficiency virus type 1 variants. Virology, 2011, 412, 269-277.	1.1	17
141	Polymorphism in HIV-1 dependency factor PDE8A affects mRNA level and HIV-1 replication in primary macrophages. Virology, 2011, 420, 32-42.	1.1	6
142	HIV-1 and the macrophage. Future Virology, 2011, 6, 187-208.	0.9	11
143	Genome-Wide Association Scan in HIV-1-Infected Individuals Identifying Variants Influencing Disease Course. PLoS ONE, 2011, 6, e22208.	1.1	40
144	Protein X of Hepatitis B Virus: Origin and Structure Similarity with the Central Domain of DNA Glycosylase. PLoS ONE, 2011, 6, e23392.	1.1	26

#	Article	IF	Citations
145	Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. Aids, 2010, 24, 939.	1.0	0
146	Genetic composition of replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC), HIV-1 proviral DNA from PBMC and HIV-1 RNA in serum in the course of HIV-1 infection. Virology, 2010, 405, 492-504.	1.1	20
147	Storage and regulated secretion of factor VIII in blood outgrowth endothelial cells. Haematologica, 2009, 94, 670-678.	1.7	32
148	Donor variation in in vitro HIV-1 susceptibility of monocyte-derived macrophages. Virology, 2009, 390, 205-211.	1.1	41
149	Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. Aids, 2009, 23, 19-28.	1.0	79
150	Isolation and propagation of HIV-1 on peripheral blood mononuclear cells. Nature Protocols, 2008, 3, 363-370.	5.5	53
151	The Effect of Trim5 Polymorphisms on the Clinical Course of HIV-1 Infection. PLoS Pathogens, 2008, 4, e18.	2.1	111
152	A Nonprogressive Clinical Course in HIVâ€Infected Individuals Expressing Human Leukocyte Antigen B57/5801 Is Associated with Preserved CD8⁺T Lymphocyte Responsiveness to the HW9 Epitope in Nef. Journal of Infectious Diseases, 2008, 197, 871-879.	1.9	34
153	Polymorphisms in the Regulatory Region of the Cyclophilin A Gene Influence the Susceptibility for HIV-1 Infection. PLoS ONE, 2008, 3, e3975.	1.1	27
154	Molecular Evolution of Human Immunodeficiency Virus Type 1 upon Transmission between Human Leukocyte Antigen Disparate Donor-Recipient Pairs. PLoS ONE, 2008, 3, e2422.	1.1	21
155	Viral Replication Capacity as a Correlate of HLA B57/B5801-Associated Nonprogressive HIV-1 Infection. Journal of Immunology, 2007, 179, 3133-3143.	0.4	86
156	The presence of the Trim5Î± escape mutation H87Q in the capsid of late stage HIV-1 variants is preceded by a prolonged asymptomatic infection phase. Aids, 2007, 21, 2015-2023.	1.0	27
157	Efficient Transduction of Simian Cells by HIV-1-based Lentiviral Vectors that Contain Mutations in the Capsid Protein. Molecular Therapy, 2007, 15, 930-937.	3.7	16
158	Shear stress sustains atheroprotective endothelial KLF2 expression more potently than statins through mRNA stabilization. Cardiovascular Research, 2006, 72, 231-240.	1.8	112
159	Determination of Co-Receptor Usage of HIV-1. , 2005, 304, 327-332.		5
160	Determination of Cell Tropism of HIV-1. , 2005, 304, 317-326.		5
161	GENETHERAPY WITHVIRALVECTORS. Annual Review of Pharmacology and Toxicology, 2003, 43, 413-439.	4.2	242
162	Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 1298-1303.	3.3	167

#	Article	IF	Citations
163	Efficient production of human FVIII in hemophilic mice using lentiviral vectors. Molecular Therapy, 2003, 7, 623-631.	3.7	104
164	Efficient Transduction of Liver and Muscle after in Utero Injection of Lentiviral Vectors with Different Pseudotypes. Molecular Therapy, 2002, 6, 349-358.	3.7	98
165	Transduction of Liver Cells by Lentiviral Vectors: Analysis in Living Animals by Fluorescence Imaging. Molecular Therapy, 2001, 3, 319-322.	3.7	118
166	Diminished Human Immunodeficiency Virus Type 1 Reverse Transcription and Nuclear Transport in Primary Macrophages Arrested in Early G1 Phase of the Cell Cycle. Journal of Virology, 2000, 74, 1712-1717.	1.5	58
167	Phenotype of HIV-1 Lacking a Functional Nuclear Localization Signal in Matrix Protein ofgagand Vpr Is Comparable to Wild-Type HIV-1 in Primary Macrophages. Virology, 1999, 253, 170-180.	1.1	47
168	R5 Strains of Human Immunodeficiency Virus Type 1 from Rapid Progressors Lacking X4 Strains Do Not Possess X4-Type Pathogenicity in Human Thymus. Journal of Virology, 1999, 73, 7817-7822.	1.5	20
169	Proliferation-Dependent Replication in Primary Macrophages of Macrophage-Tropic HIV Type 1 Variants. AIDS Research and Human Retroviruses, 1998, 14, 339-345.	0.5	18
170	Infectious Cellular Load in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals and Susceptibility of Peripheral Blood Mononuclear Cells from Their Exposed Partners to Non-Syncytium-Inducing HIV-1 as Major Determinants for HIV-1 Transmission in Homosexual Couples. Journal of Virology, 1998, 72, 218-224.	1.5	31
171	Analysis of the Temporal Relationship between Human Immunodeficiency Virus Type 1 Quasispecies in Sequential Blood Samples and Various Organs Obtained at Autopsy. Journal of Virology, 1998, 72, 488-496.	1.5	133
172	Analysis of CD8⁺T Lymphocyte-Mediated Nonlytic Suppression of Autologous and Heterologous Primary Human Immunodeficiency Virus Type 1 Isolates. AIDS Research and Human Retroviruses, 1997, 13, 685-693.	0.5	16
173	IL-10 and HIV-1 Replication. Molecular Biology Intelligence Unit, 1995, , 101-112.	0.2	0
174	Productive HIV-1 infection of macrophages restricted to the cell fraction with proliferative capacity.. EMBO Journal, 1994, 13, 5929-5936.	3.5	84
175	Viro-immunological studies in acute HIV-1 infection. Aids, 1994, 8, 1533-1538.	1.0	32
176	Early Replication Steps but Not Cell Type-Specific Signalling of the Viral Long Terminal Repeat Determine HIV-1 Monocytotropism. AIDS Research and Human Retroviruses, 1993, 9, 669-675.	0.5	21
177	Lack of T Cell Dysfunction and Programmed Cell Death in Human Immunodeficiency Virus Type 1-Infected Chimpanzees Correlates with Absence of Monocytotropic Variants. Journal of Infectious Diseases, 1993, 168, 1140-1147.	1.9	113
178	Differential Tropism of Clinical HIV-1 Isolates for Primary Monocytes and Promonocytic Cell Lines. AIDS Research and Human Retroviruses, 1992, 8, 1679-1682.	0.5	33
179	Viral and Cellular Requirements for HIV-1 Infection in Monocytes1. , 1992, , 253-264.		0
180	Induction of monocyte proliferation and HIV expression by IL-3 does not interfere with anti-viral activity of zidovudine. Blood, 1990, 76, 1490-1493.	0.6	30

#	Article	IF	Citations
181	Neurodevelopmental delay in pediatric HIV/AIDS: current perspectives. Neurobehavioral HIV Medicine, 0, , 1.	2.0	9
182	Efficient Transduction of Simian Cells by HIV-1-based Lentiviral Vectors that Contain Mutations in the Capsid Protein. Molecular Therapy, 0, , .	3.7	0
183	Identification of Liver and Plasma microRNAs in Chronic Hepatitis B Virus infection. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	7